First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial.

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial.
May 9, 2020 0 Comments

FunctionCirculating tumor cells (CTCs) are prognostic biomarkers in metastatic breast most cancers, however their position in predicting therapy outcomes in metastatic triple-negative breast most cancers (mTNBC) is much less clear. The tnAcity trial demonstrated a major progression-free survival (PFS) profit with nab-paclitaxel (nab-P)/carboplatin (C) over nab-P/gemcitabine (G) or G/C in sufferers with mTNBC. We assessed the correlation between CTC dynamics …